Everyone's Watching SpaceX -- but This IPO Stock Could Have Much Bigger Upside

Oura filed confidential IPO paperwork on May 21, 2026, with a 2025 revenue run-rate of about $1 billion and management targeting nearly $2 billion in 2026 sales. The company was valued at $11 billion in its October 2025 funding round, implying roughly 5.5x projected 2026 sales, but faces major competition from Apple and Samsung in smart rings and wearables. The article frames Oura as a more reasonably priced, less capital-intensive IPO than SpaceX, with upside tied to profitable growth and recurring subscriptions.

Analysis

Oura’s IPO is less about one consumer gadget and more about the emergence of a recurring-revenue health-data platform with materially cleaner unit economics than the market’s usual hardware narratives. The key second-order effect is that a successful listing would validate consumer wearables as a subscription business, which should compress the valuation gap between device makers and software-like health platforms. That matters not just for AAPL, but also for Samsung’s adjacent hardware ambitions and any venture-backed “health OS” companies relying on premium multiples to fund growth.

The market may be underestimating how quickly a credible, public Oura could force incumbents to respond on feature bundling and pricing. If Apple accelerates smart-ring development, the initial threat is not ring economics but ecosystem pressure: bundling against Watch, AirPods, and Health could turn Oura’s differentiation into a retention battle rather than a category expansion story. That would likely cap Oura’s multiple before revenue saturates, because the moat is data continuity, not hardware lock-in.

The near-term catalyst is IPO timing and roadshow positioning; the medium-term catalyst is whether international growth can sustain subscription attach rates without higher churn. The main tail risk is that consumer wearables get repriced as replaceable accessories if the big platforms decide the category matters. Over 6-18 months, the most important variable is not TAM rhetoric but whether Oura can prove cohort durability and margin resilience against lower-priced imitators and ecosystem copycats.

Key Decisions for Investors

• Buy AAPL put spreads 3-6 months out as a low-cost hedge against ring/care-wearable strategic escalation; the setup is less about immediate earnings impact and more about optionality if Apple signals category entry.
• Avoid chasing OURA at IPO if pricing clears materially above ~6x forward sales; the best entry is likely post-lockup or after the first quarter of public numbers when subscription churn and cohort retention are visible.
• Pair trade: long OURA on weakness vs short a basket of consumer-hardware peers that lack software monetization; if the IPO screens well, capital should rotate toward subscription-enabled devices over one-time hardware sales.
• For catalyst traders, buy short-dated straddles on AAPL into any management commentary about wearables/health roadmap; implied volatility should be cheap relative to the strategic headline risk.
• If OURA lists below the market’s growth comps and shows >100% net revenue retention-style behavior in public filings, add aggressively over 1-2 quarters; the risk/reward improves sharply if investors treat it as a health-data platform rather than a gadget company.